Inveready, a venture capital management firm and CataloniaBio & HealthTech member, has closed its first vehicle, Inveready Seed Capital SCR, after 11 years with returns of €100 million.
Inveready Seed Capital was created to invest in early-stage technology companies and, in total, the fund has participated in 35 firms, 40% in the healthcare and life sciences sector. The life sciences portfolio out-performed investment five-fold.
“We are very pleased with the return on this fund, one of the sector's most successful in Europe, as well as its social and economic impact,” notes Inveready President Josep Maria Echarri.
The fund has carried out investments and disinvestments in biotechnology firms like Palobiofarma, licensing part of the pipeline to Novartis, and taking Atrys Health public on the BME Growth market.
Photo: Josep Maria Echarri, Carlos Conti, Ignacio Fonts and Roger Piqué, partners of Inveready - © Inveready
You may also be interested in:
Comments